Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes

NCT02254291 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02254291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02254291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
October 2, 2014
Completion date
November 11, 2015
Enrollment
308 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2